APTT	Activated partial thromboplastin time
Ara-C	Cytosine arabinoside
AST	Aspartate aminotransferase
BBB	Blood–brain barrier
CAR-T	Chimeric antigen receptor T
CNS	Cerebral nervous system
CR	Complete remission
Cr	Creatinine
CRP	C-reactive protein
CRS	Cytokine release syndrome
Cy	Cyclophosphamide
DOR	Duration of response
EMA	European Medicines Agency
FDA	Food and Drug Administration
Flu	Fludarabine
G-CSF	Granulocyte -colony stimulating factor
GGT	Gamma-glutamyl transpeptidase
GM-CSF	granulocyte-macrophage colony-stimulating factor
HB	Hemoglobin
HSCT	Hematopoietic stem cell transplantation
HSCT	Hematopoietic stem cell transplantation
HSCT	Hematopoietic stem cell transplantation
ICANS	Immune effector cell associated neurotoxicity syndrome
IFN-γ	Interferon-γ
IL-10	Interleukin-10
IL-6	Interleukin-6
IQR	Interquartile
MCP-1	Monocyte chemoattractant protein 1
mCRS	Mild CRS
MRD	Minimal residual disease
NR	No remission
NT-proBNP	N-terminal pro-brain natriuretic peptide
ORR	Overall response rate
OS	Overall survival
PLT	Platelet
PR	Partial remission
PT	Prothrombin time
r/r B-ALL	Relapsed or refractory B-cell acute lymphoblastic leukemia
r/r DLBCL	Relapsed or refractory diffuse large B-cell lymphoma
r/r MCL	Relapsed or refractory mantle-cell lymphoma
scFv	Single chain variable fragment
sCRS	Severe CRS
SD	Standard deviation
shRNA	Short hairpin RNA
ssCAR-T-19	IL-6 knocking down CD19 CAR-T
TB	Total bilirubin